Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02319044 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT02319044 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 267 participants.
The verdict
NCT02319044, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.
Interventions
- DRUG Tremelimumab
- DRUG MEDI4736
- DRUG MEDI4736 + Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2015-04-15 |
| Est. Completion | 2020-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02319044
The ClinicalTrials.gov registry entry for NCT02319044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tremelimumab is the first listed.
NCT02319044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02319044 about?
NCT02319044 is a clinical study titled "Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have pr...
What is the current status of trial NCT02319044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2015-04-15. Estimated completion is 2020-07-06.
What interventions are being tested in trial NCT02319044?
The interventions under investigation include: Tremelimumab (DRUG), MEDI4736 (DRUG), MEDI4736 + Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02319044?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.